MULTI-STAKEHOLDER DISCUSSIONS
The CDDF offers conferences, workshops, webinars, and projects that bring together stakeholders involved in oncology. In a neutral, non-competitive environment, we foster productive dialogue and open, respectful interactions in collaboration with the European Medicines Agency (EMA), the US Food and Drug Administration (FDA), and regulators from Europe and worldwide, alongside with academic researchers, pharmaceutical companies, HTA bodies, and patient advocates.
The CDDF Annual Conference is a unique multi-stakeholder meeting that gathers key stakeholders and experts to address challenges and opportunities in oncology drug development. This interactive three-day meeting features plenary lectures with moderated discussions, offering multistakeholder perspectives and unique networking opportunities. In addition to the Conference, the CDDF organizes workshops, webinars and EU-level projects to facilitate multi-stakeholder collaboration on topical issues in the field of oncology. The responsive nature of the CDDF platform enables the oncology community to initiate timely conversations to reflect current and pressing needs.
Upcoming events
Past events
Multi-Stakeholder Platform Advisory Group – Accelerating Clinical Trials in the EU
The CDDF takes part in the Multi-Stakeholder Platform Advisory Group (MSP AG) under the Accelerating Clinical Trials in the EU (ACT EU). As an ad hoc representative of MSP AG, the CDDF provides multi-stakeholder input on key topics in drug development and collaborate with regulators and other stakeholders to enhance clinical trials within the European landscape.
CDDF Diversity Initiative
The CDDF has launched its Diversity Initiative in August 2024 to examine parameters of inclusion/diversity to support planning and evaluation of clinical research and the applicability of clinical trial outcomes to Europe’s diverse population. This initiative is a CDDF-sponsored and directed project with a multi-stakeholder working group of regulators, payers, patients, academic researchers, and pharmaceutical companies.